Patents by Inventor Jeff A. Zablocki

Jeff A. Zablocki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SUBSTITUTED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS
    Publication number: 20100125091
    Abstract: The present invention relates to sodium channel inhibitors of Formula (I): in which R1, R2, R3, R4, R5, X, Y, and Z are as defined herein, and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. The invention also relates to methods for the preparation of the compounds, and to pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: November 12, 2009
    Publication date: May 20, 2010
    Applicant: Gilead Palo Alto, Inc.
    Inventors: Matthew Abelman, Robert Jiang, Jeff Zablocki
  • Partial and full agonists Aadenosine receptors
    Patent number: 7713946
    Abstract: Disclosed are novel compounds a compound of Formula I that are partial and full A1 adenosine receptor agonists, useful for treating various disease states, in particular dyslipidemia, diabetes, decreased insulin sensitivity, Polycystic Ovarian Syndrome, Stein-Leventhal syndrome, and obesity.
    Type: Grant
    Filed: December 18, 2006
    Date of Patent: May 11, 2010
    Assignee: CV Therapeutics, Inc.
    Inventors: Arvinder Dhalla, Elfatih Elzein, Prabha Ibrahim, Venkata Palle, Vaibhav Varkhedkar, Jeff Zablocki
  • FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS
    Publication number: 20100113449
    Abstract: The present invention relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula (IA) or (IB): as further described herein. The invention also relates to methods for the preparation of the compounds, and to pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: October 28, 2009
    Publication date: May 6, 2010
    Applicant: Gilead Palo Alto, Inc.
    Inventors: Matthew Abelman, Elfatih Elzein, Robert Jiang, Rao Kalla, Tetsuya Kobayashi, Xiaofen Li, Thao Perry, Jeff Zablocki
  • FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS
    Publication number: 20100113514
    Abstract: The present invention relates to sodium channel inhibitors of Formula : in which R1, R2, R3, R4, R5, R6, and R7 are as defined above, and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes.
    Type: Application
    Filed: October 28, 2009
    Publication date: May 6, 2010
    Applicant: Gilead Palo Alto, Inc.
    Inventors: Matthew Abelman, Nancy Chu, Robert Jiang, Kwan Leung, Jeff Zablocki
  • SUBSTITUTED HETEROCYCLIC COMPOUNDS
    Publication number: 20100113461
    Abstract: The present invention relates to compounds that are late sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula (I): wherein R1, R2, R3, and R4 are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.
    Type: Application
    Filed: October 27, 2009
    Publication date: May 6, 2010
    Applicant: Gilead Palo Alto, Inc.
    Inventors: Dmitry Koltun, Eric Parkhill, Jeff Zablocki
  • PTERIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
    Publication number: 20100113463
    Abstract: The present invention discloses pteridinone derivatives for use as inhibitors of stearoyl-CoA desaturase having the structure of Formula I: The compounds are useful in treating and/or preventing various human diseases, mediated by stearoyl-CoA desaturase (SCD) enzymes, especially diseases related to abnormal lipid levels, cardiovascular disease, diabetes, obesity, metabolic syndrome and the like.
    Type: Application
    Filed: January 7, 2010
    Publication date: May 6, 2010
    Applicant: Gilead Palo Alto, Inc.
    Inventors: Jeffrey Chisholm, Dmitry Koltun, Jeff Zablocki, Eric Parkhill, Andrey Glushkov, Natalya Vasilevich, Timur Zilbershtein, Andrew Cole, Tsung Lin, Ian Henderson
  • Partial and full agonists of Aadenosine receptors
    Patent number: 7696181
    Abstract: Disclosed are novel compounds that are partial and full A1 adenosine receptor agonists, useful for treating various disease states, in particular tachycardia and atrial flutter, angina, myocardial infarction and hyperlipidemia. The structure of the compounds is given by Formula (I): wherein R1, R2, R3, R4, R5, X, Y, Z, and T are as described herein.
    Type: Grant
    Filed: August 24, 2006
    Date of Patent: April 13, 2010
    Assignee: CV Therapeutics, Inc.
    Inventors: Prabha Ibrahim, Elfatih Elzein, Kevin Shenk, Robert Jiang, Jeff Zablocki, Xiaofen Li, Christopher Morrison, Thao Perry, Dengming Xiao
  • C-Pyrazole A2A Receptor Agonists
    Publication number: 20100081810
    Abstract: 2-adenosine C-pyrazole compounds having formula (a) and methods for using the compounds as A2A receptor agonists to stimulate mammalian coronary vasodilatation for therapeutic purposes and for purposes of imaging the heart.
    Type: Application
    Filed: June 25, 2009
    Publication date: April 1, 2010
    Inventors: Jeff A. Zablocki, Elfatih O. Elzein, Venkata P. Palle
  • Pro-drugs of A2B Adenosine Receptor Antagonists
    Publication number: 20100056538
    Abstract: Disclosed are prodrugs of A2B adenosine receptor antagonists, and their use in treating mammals for various disease states.
    Type: Application
    Filed: November 13, 2009
    Publication date: March 4, 2010
    Applicant: Gilead Palo Alto, Inc.
    Inventors: Rao Kalla, Dmitry Koltun, Jeff Zablocki, Elfatih Elzein
  • Process for preparing an A-adenosine receptor agonist and its polymorphs
    Patent number: 7671192
    Abstract: Synthesis methods suitable for large scale manufacture of the A2A-adenosine receptor agonist (1-{9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminopurin-2-yl}pyrazol-4-yl)-N-methylcarboxamide and precursors thereof.
    Type: Grant
    Filed: May 17, 2007
    Date of Patent: March 2, 2010
    Assignee: Gilead Palo Alto, Inc.
    Inventors: Jeff Zablocki, Elfatih Elzein
  • Pteridinone derivatives for use as stearoyl CoA desaturase inhibitors
    Patent number: 7662819
    Abstract: The present invention discloses pteridinone derivatives for use as inhibitors of stearoyl-CoA desaturase having the structure of Formula I: The compounds are useful in treating and/or preventing various human diseases, mediated by stearoyl-CoA desaturase (SCD) enzymes, especially diseases related to abnormal lipid levels, cardiovascular disease, diabetes, obesity, metabolic syndrome and the like.
    Type: Grant
    Filed: October 5, 2007
    Date of Patent: February 16, 2010
    Assignee: Gilead Palo Alto, Inc.
    Inventors: Jeffrey Chisholm, Dmitry Koltun, Jeff Zablocki, Eric Parkhill, Andrey Glushkov, Natalya Vasilevich, Timur Zilbershtein, Andrew Cole, Tsung Lin, Ian Henderson
  • N-pyrazole Areceptor agonists
    Patent number: 7655637
    Abstract: 2-adenosine N-pyrazole compounds having the following formula: wherein R1?CH2OH; R2 is hydrogen; R3 is selected from the group consisting of CO2R20; —CONR7R8 ,and aryl wherein the aryl substituent is optionally substituted with one substituent selected from the group consisting of halo, C 1-3alkyl and OR20;R4 is hydrogen; R7 is selected from hydrogen, and C1-3alkyl; R8 is hydrogen; and R20 is selected from hydrogen and methyl as well as methods for using the compositions as A2A receptor agonists to stimulate mammalian coronary vasodilatation for therapeutic purposes and for purposes of imaging the heart are disclosed.
    Type: Grant
    Filed: October 27, 2006
    Date of Patent: February 2, 2010
    Assignee: Gilead Palo Alto, Inc.
    Inventors: Jeff A. Zablocki, Elfatih O. Elzein, Venkata Palle, Luiz Belardinelli
  • Partial and full agonists of Aadenosine receptors
    Patent number: 7655638
    Abstract: Disclosed are novel compounds that are partial and full A1 adenosine receptor agonists, useful for treating various disease states, in particular tachycardia and atrial flutter, angina, and myocardial infarction.
    Type: Grant
    Filed: November 15, 2006
    Date of Patent: February 2, 2010
    Assignee: Gilead Palo Alto, Inc.
    Inventors: Elfatih Elzein, Prabha Ibrahim, Venkata Palle, Vaibhav Varkhedkar, Jeff Zablocki
  • PARTIAL AND FULL AGONISTS OF A1 ADENOSINE RECEPTORS
    Publication number: 20090325896
    Abstract: Disclosed are novel compounds that are partial and full A1 adenosine receptor agonists, useful for treating various disease states, in particular tachycardia and atrial flutter, angina, myocardial infarction and hyperlipidemia.
    Type: Application
    Filed: July 23, 2009
    Publication date: December 31, 2009
    Inventors: Prabha Ibrahim, Elfatih Elzein, Kevin Shenk, Robert Jiang, Jeff Zablocki, Xiaofein Li, Christopher Morrison, Thao Perry, Dengming Xiao
  • Prodrugs of Aadenosine receptor antagonists
    Patent number: 7625881
    Abstract: Disclosed are prodrugs of A2B adenosine receptor antagonists, having the following structure and their use in treating mammals for various disease states.
    Type: Grant
    Filed: June 14, 2006
    Date of Patent: December 1, 2009
    Assignee: Gilead Palo Alto, Inc.
    Inventors: Rao Kalla, Dmitry Koltun, Jeff Zablocki, Elfatih Elzein
  • Substituted heterocyclic compounds
    Patent number: 7601721
    Abstract: Disclosed are novel piperazine and piperazine derivatives, useful for the treatment of various disease states, in particular cardiovascular diseases such as atrial and ventricular arrhythmias, diabetes, intermittent claudication, Prinzmetal's (variant) angina, stable and unstable angina, exercise induced angina, congestive heart disease, and myocardial infarction.
    Type: Grant
    Filed: September 17, 2007
    Date of Patent: October 13, 2009
    Assignee: Gilead Palo Alto, Inc.
    Inventors: Jeff Zablocki, Dmitry Koltun
  • TRIAZOLOPYRIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
    Publication number: 20090253738
    Abstract: The present invention discloses triazolopyridinone derivatives for use as inhibitors of stearoyl-CoA desaturase having the structure of Formula I: The compounds are useful in treating and/or preventing various human diseases, mediated by stearoyl-CoA desaturase (SCD) enzymes, especially diseases related to abnormal lipid levels, cardiovascular disease, diabetes, obesity, metabolic syndrome and the like.
    Type: Application
    Filed: April 3, 2009
    Publication date: October 8, 2009
    Inventors: Dmitry Koltun, Jeff Zablocki
  • 2H-BENZO[b][1,4]OXAZIN-3(4H)-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
    Publication number: 20090253693
    Abstract: The present invention discloses 2H-benzo[b][1,4]oxazin-3(4H)-one derivatives for use as inhibitors of stearoyl-CoA desaturase having the structure of Formula I: The compounds are useful in treating and/or preventing various human diseases, mediated by stearoyl-CoA desaturase (SCD) enzymes, especially diseases related to abnormal lipid levels, cardiovascular disease, diabetes, obesity, metabolic syndrome and the like.
    Type: Application
    Filed: April 3, 2009
    Publication date: October 8, 2009
    Inventors: Dmitry Koltun, Jeff Zablocki, Natalya Vasilevich, Vasily Migulin
  • PYRROLOTRIAZINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
    Publication number: 20090253704
    Abstract: The present invention discloses pyrrolotriazinone derivatives for use as inhibitors of stearoyl-CoA desaturase having the structure of Formula I: The compounds are useful in treating and/or preventing various human diseases, mediated by stearoyl-CoA desaturase (SCD) enzymes, especially diseases related to abnormal lipid levels, cardiovascular disease, diabetes, obesity, metabolic syndrome and the like.
    Type: Application
    Filed: April 3, 2009
    Publication date: October 8, 2009
    Inventors: Dmitry Koltun, Eric Parkhill, Jeff Zablocki
  • PARTIAL AND FULL AGONISTS OF A1 ADENOSINE RECEPTORS
    Publication number: 20090247557
    Abstract: Disclosed are novel compounds a compound of Formula I that are partial and full A1 adenosine receptor agonists, useful for treating various disease states, in particular dyslipidemia, diabetes, decreased insulin sensitivity, Polycystic Ovarian Syndrome, Stein-Leventhal syndrome, and obesity.
    Type: Application
    Filed: April 2, 2009
    Publication date: October 1, 2009
    Inventors: Arvinder Dhalla, Elfatih Elzein, Prabha Ibrahim, Venkata Palle, Vaibhav Varkhedkar, Jeff Zablocki